Motilal Oswal - Repco Home Finance (REPCOHOME) MOSL: REPCO HOME FINANCE (Buy)-Loan growth largely stable; asset quality under pressure

Report

Motilal Oswal

Alpesh Mehta

EUR 120.00 For Business Accounts Only

MOSL: REPCO HOME FINANCE (Buy)-Loan growth largely stable; asset quality under pressure

REPCO HOME FINANCE: Loan growth largely stable; asset quality under pressure

(REPCO IN, Mkt Cap USD0.3b, CMP INR289, TP INR370, 28% Upside, Buy)

REPCO's PAT was up 51% YoY at INR1.01b (37% beat), driven by low credit costs and a 1% tax rate (INR150m DTL reversal impact). Core PBT, however, grew 2% YoY to INR1.02b (4% beat).
Disbursements were down 10% YoY at INR7b, driven by a decline in both home loan and LAP disbursements. Although overall loan growth was largely stable at 11% YoY, it was sluggish at 7% YoY in Tamil Nadu (56% of book). Overall loan book stood at INR115b.
Reported spreads were largely stable YoY at 3.1%, as the 30bp increase in cost of funds (to 8.5%) was offset by a similar rise in yields (to 11.6%). REPCO carried INR5b+ of liquidity on the balance sheet versus INR500m in 4QFY19.

15/11/2019 12 EN

Underlying

Repco Home Finance

Repco Home Finance Limited is an India-based housing finance company. The Company provides a range of home loan products to individual borrowers in both the salaried and non-salaried (self-employed professional and self-employed non-professional) segments to suit various requirements. The Company has presence in two segments: Individual Home Loans and Loans Against Property. The Company's loans for construction or purchase of house property include Dream Home Loan, Super Loan, Fifty Plus Loan, NRI Housing Loan, New Horizon Loan, Repco - Rural Loan and Repco - Premium Loan. The Company's loans for repair and renovation/extension of existing property include Home Makeover Loan. The Company offers loans for purchase of plots, such as Plot Loans. The Company offers loans against property, such as Prosperity loan. The Company has a network of approximately 150 branches/satellite centers. The Company also offers Repco - Delight, New Horizon Loan and Commercial Real Estate (CRE) Loan.

See profile

INE612J01015 National Stock Exchange of India India

Provider

Motilal Oswal

Motilal Oswal Financial Services Ltd. is a reputed name in Financial Services and Online Trading with group companies providing services such as Private Wealth Management, Retail Broking and Distribution, Institutional Broking, Asset Management, Investment Banking, Private Equity, Commodity Broking, Currency Broking, Principal Strategies & Home Finance.

Motilal Oswal Securities is a group company of Motilal Oswal Financial Service Limited which started as a stock trading company and has blossomed into well diversified firm offering a range of financial products and services. Motilal Oswal has built a reputation as the source for best stock trading company and this has taken a wealth of experience, knowledge and expertise, constantly working in tandem, over the years.

See profile

Analysts

Alpesh Mehta

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Motilal Oswal

MOSL: REPCO HOME FINANCE (Buy)-In-line operating performance; asset quality stable

Repco Home Finance: In-line operating performance; asset quality stable (REPCO IN, Mkt Cap USD0.3b, CMP INR325, TP INR390, 20% Upside, Buy) PAT increased 25% YoY to INR697m (2% beat) in 3QFY20. While NII was largely in line with our estimate, higher opex (7% miss) was offset by lower provisioning (11% beat), leading to largely in-line PAT. Loan book grew 1% QoQ/9% YoY to INR116b, driven by sluggish growth in Tamil Nadu (TN; +6% YoY). Reported spreads improved 20bp QoQ/YoY to 3.3%, while the GNPL ratio was sequentially stable at 4.2%. We largely maintain our estimates. Buy with a targe...

EUR 120.00

February 11, 2020 February 11, 2020 12 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 17.01

November 25, 2019 November 25, 2019 14 EN

MOSL : HOME FIRST FINANCE COMPANY: Earnings in-line with sustained improvement in asset quality

HOME FIRST FINANCE COMPANY: Earnings in-line with sustained improvement in asset quality (HOMEFIRS IN, Mkt Cap USD0.9b, CMP INR802, TP INR1025, 28% Upside, Buy) HomeFirst’s 2QFY23 PAT grew 21% YoY/6% QoQ to INR543m (in-line). Credit costs grew 37% QoQ to INR50m (MOFSLe: INR31m). Underlying this, the NII grew 58% YoY to ~INR1b (in-line). ‘Other income’ grew 13% QoQ, driven primarily by higher treasury gains and investment income. Opex was 7% higher than estimated and grew 47% YoY and 14% QoQ, led by investments in new branches and resultant higher employee expenses. Disbursements grew 36%...

EUR 120.00

October 21, 2022 October 21, 2022 12 EN

Aliasgar Shakir

Aliasgar Shakir

MOSL : SHOPPERS STOP: Ticking the right boxes

. SHOPPERS STOP: Ticking the right boxes (SHOP IN, Mkt Cap USD1b, CMP INR780, TP INR805, 3% Upside, Neutral) Aided by price hikes, SHOP reported a healthy 19% revenue growth in 2QFY23 from pre-COVID levels (8% beat) on healthy (+10%) SSSG and sustained volumes. EBITDA grew 2.3x YoY (22% over pre-COVID levels), with a 540bp margin improvement. 1) A strong recovery in revenue, backed by an improved pricing; 2) expansion within the Beauty and Private Label segment; and 3) healthy annual 12/15 store additions for SHOP/Beauty are expected to drive business growth going forward. We expect a r...

EUR 120.00

October 21, 2022 October 21, 2022 13 EN

Tushar Manudhane

Tushar Manudhane

MOSL : ERIS LIFESCIENCES: Enhanced efforts toward product launch-related activities

ERIS LIFESCIENCES: Enhanced efforts toward product launch-related activities (ERIS IN, Mkt Cap USD1.2b, CMP INR708, TP INR860, 21% Upside, Buy) Eris Lifesciences (ERIS) delivered better than expected 2QFY23 performance, led by superior traction in new launches and improved operating leverage. ERIS is notonly sustaining the momentum in its recently launched products, but it is also preparing itself for an aggressive pace of new introductions. We reiterate our earnings estimate for FY23/FY24 and continue to value ERIS at 22x 12M forward earnings to arrive at a price target of INR860. We re...

EUR 120.00

October 21, 2022 October 21, 2022 11 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MOSL: REPCO HOME FINANCE (Buy)-Loan growth largely stable; asset quality under pressure

Monthly LMI Update Independent Investment Research

MOSL: REPCO HOME FINANCE (Buy)-In-line operating performance; asset quality stable

Feasibility Study Results in December to be a Catalyst for this Junior

MOSL : HOME FIRST FINANCE COMPANY: Earnings in-line with sustained improvement in asset quality

MOSL : SHOPPERS STOP: Ticking the right boxes

MOSL : ERIS LIFESCIENCES: Enhanced efforts toward product launch-related activities

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe